Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Refractoriness to platelet transfusion.

Paolo Rebulla1

  • 1Centro Trasfusionale e di Immunologia dei Trapianti, IRCCS Ospedale Maggiore, Milan, Italy. prebulla@libero.it

Current Opinion in Hematology
|October 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Quality and stability studies of red blood cell concentrates from umbilical cord blood compared to their adult counterparts.

Blood transfusion = Trasfusione del sangue·2026
Same author

Characterization of allogeneic platelet gel from adult donor blood and umbilical cord blood activated with locally prepared cryoprecipitate and thrombin: A pilot exercise.

Transfusion·2026
Same author

Meta-analysis of efficacy and safety of pathogen-reduced platelet components: Request for clarification.

Vox sanguinis·2024
Same author

In vitro regenerative effects of a pooled pathogen-reduced lyophilized human cord blood platelet lysate for wound healing applications.

Blood transfusion = Trasfusione del sangue·2024
Same author

Editorial Expression of Concern: Cell Lines Derived from Human Parthenogenetic Embryos Can Display Aberrant Centriole Distribution and Altered Expression Levels of Mitotic Spindle Check-point Transcripts.

Stem cell reviews and reports·2024
Same author

Quality and stability studies of red blood cell concentrates from umbilical cord blood compared to their adult counterparts.

Blood transfusion = Trasfusione del sangue·2024
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Platelet refractoriness, a complication affecting leukemia patients, can be managed with HLA-typed donors, cross-matching, or antibody prediction. Choosing the best approach depends on available resources and expertise.

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Immunology

Background:

  • Platelet refractoriness is a significant complication following platelet transfusions.
  • It impacts a variable proportion of patients, influenced by diagnosis, prior immune exposure, and blood product type.
  • Incidence rates range from 3-4% for white cell-reduced components to 13% for traditional products in acute leukemia patients.

Purpose of the Study:

  • To review the underlying causes of platelet refractoriness.
  • To present and discuss current management strategies for platelet refractoriness.
  • To explore emerging concepts in the field.

Main Methods:

  • Literature review of causes and management of platelet refractoriness.
  • Analysis of recent study data on incidence rates.

Related Experiment Videos

  • Discussion of three primary management options: HLA-typed donors, platelet cross-matching, and antibody specificity prediction.

    • Main Results:

    • Platelet refractoriness occurs in 13% of acute leukemia patients receiving traditional products and 3-4% receiving white cell-reduced components.
    • Key management strategies include using platelets from HLA-typed donors, employing platelet cross-matching techniques, and utilizing antibody specificity prediction.
    • The choice of management strategy is contingent upon local resources, economic factors, and available expertise.

    Conclusions:

    • Platelet refractoriness necessitates careful consideration of patient-specific factors and available resources for effective management.
    • Current management options offer viable solutions, with emerging concepts promising future advancements.
    • Optimizing transfusion strategies is crucial for improving patient outcomes in hematologic malignancies and other conditions.